The Effects of Probiotic Supplementation on Glycemic index, Lipid Profiles and Inflammatory cytokines in NAFLD Patients: A Protocol for a Systematic Review and Meta-Analysis

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver disorders worldwide. In an aggressive type, non-alcoholic steatohepatitis (NASH) might lead to cirrhosis and hepatocellular carcinoma progression. Currently, there is no certified drug applied to treat NASH. Human studies have demonstrated the beneficial effects of probiotics supplementation in NAFLD. Due to the lack of appropriate studies and the emerging requirements for further illustration over the effects of probiotics on the treatment of NAFLD and NASH-related disorders in humans, in this study, we seek to evaluate this matter often papered over. Methods: We will search PubMed, EMBASE, Cochrane Library, and Web of Science from inception to February 2021. Search terms are keywords and medical subject headings related to NAFLD, probiotics, glycemic indexes, inflammation, and dyslipidemia. 2 researchers will determine the search strategy after several pre-searches. The Glycemic outcomes include glycated hemoglobin, fasting blood glucose, fasting insulin, homeostasis model assessment of insulin resistance. The lipidomic outcomes include differences in High-density lipoprotein, Low-density lipoprotein, Total triglyceride, Total cholesterol. The Inflammatory outcomes include differences in IL6, IL1β, TNFα, CRP. The meta-analysis will be performed using END NOTE and STATA. Results: Our study will systematically evaluate the effectiveness and safety of probiotics supplementation in NAFLD patients. Conclusion: This study’s results will give the proof for probiotics supplements in NAFLD treatment and provide an evidence for clinical treatment.